Sustained response of galcanezumab in migraine prevention: Patient‐level data from a post hoc analysis in patients with episodic or chronic migraine

To evaluate, at population and individual patient levels, the sustained response of reduction in migraine headache days in patients with migraine treated with galcanezumab.

• Publication year

  2023

• Venue

  Headache

• Publication date

  2023-05-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/head.14494PMID 37132481
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The beneficial effect of positive treatment expectations on pharmacological migraine prophylaxis.

  2021cited by this paper
• The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic‐specific estimates from government health surveys

  2020cited by this paper
• Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.

  2020cited by this paper
• The Prevalence and Impact of Migraine and Severe Headache in the United States: Figures and Trends From Government Health Studies

  2018cited by this paper
• Galcanezumab in chronic migraine

  2018cited by this paper
• Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial

  2018cited by this paper
• Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial

  2018cited by this paper
• 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double‐Blind, Placebo‐Controlled EVOLVE‐1 and EVOLVE‐2 Studies

  2018cited by this paper
• Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE‐1, EVOLVE‐2, and REGAIN Randomized, Double‐Blind, Placebo‐Controlled Studies

  2018cited by this paper
• The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice

  2018cited by this paper
• Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies

  2018cited by this paper
• Patients’ Expectations Regarding Medical Treatment: A Critical Review of Concepts and Their Assessment

  2017cited by this paper
• Prognostic factors for chronic headache

  2017cited by this paper
• Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis

  2016cited by this paper
• Adherence to oral migraine-preventive medications among patients with chronic migraine

  2015cited by this paper
• Systematic Review of Migraine Prophylaxis Adherence and Persistence

  2014cited by this paper
• Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study (IBMS‐II)

  2013cited by this paper
• The International Classification of Headache Disorders, 3rd edition (beta version)

  2013cited by this paper
• Prophylaxis of migraine: general principles and patient acceptance

  2008cited by this paper
• The broad treatment expectations of migraine patients

  2006cited by this paper
• Why headache treatment fails

  2003cited by this paper
• Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society.

  1988cited by this paper
• Prognostic factors for chronic headache A systematic review

  year unknowncited by this paper

• No citing papers are available for this paper.